Search Results - "Pneumococcal conjugate vaccine"

Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial by Courtney P. Olwagen, Alane Izu, Lara Van der Merwe, Lisa Jose, Anthonet Koen, Shabir A. Madhi

Connect to this object online.

Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial by Amanda Jane Leach, Edward Kim Mulholland, Mathuram Santosham, Paul John Torzillo, Peter McIntyre, Heidi Smith-Vaughan, Nicole Wilson, Beth Arrowsmith, Jemima Beissbarth, Mark D. Chatfield, Victor M. Oguoma, Peter Stanley Morris

Connect to this object online.

Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants by Nicola P. Klein, Remon Abu-Elyazeed, Yaela Baine, Brigitte Cheuvart, Marcela Silerova, Narcisa Mesaros

Connect to this object online.

The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019 by Eiman Mokaddas, Shabeera Syed, M. John Albert

Connect to this object online.

Avaliação da resposta humoral à vacina pneumocócica 7-valente em crianças com Aids Evaluación de la vacuna neumocócica 7-valente en la respuesta humoral de niños con SIDA Evaluation of humoral response to heptavalent pneumococcal conjugate vaccine in HIV-infected children by Isabel de Camargo Costa, Fabiana Guilardi, Mariana Acenjo Kmiliauskis, Christina Arslanian, Evandro Roberto Baldacci

Connect to this object online.

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors by Laura L. Hammitt, Dean Quinn, Ewa Janczewska, Francisco J. Pasquel, Richard Tytus, K. Rajender Reddy, Katia Abarca, Ilsiyar M. Khaertynova, Ron Dagan, Rachel Dawson, Jennifer McCauley, Tulin Shekar, Wei Fu, Alison Pedley, Tina Sterling, Gretchen Tamms, Luwy Musey, Ulrike K. Buchwald

Connect to this object online.

Bacterial Meningitis Epidemiology and Vaccination

Subjects: “…pneumococcal conjugate vaccines…”
DOAB: download the publication
DOAB: description of the publication

Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea by Eun Hwa Choi, Kyung Hyo Kim, Yae Jean Kim, Jong Hyun Kim, Su Eun Park, Hoan Jong Lee, Byung Wook Eun, Dae Sun Jo, Kyong Min Choi, Young Jin Hong

Connect to this object online.

Vaccine hesitancy and receipt of mandatory and optional pediatric vaccines in Shanghai, China by Mengdi Ji, Zhuoying Huang, Jia Ren, Abram L. Wagner

Connect to this object online.

Antipneumococcal vaccination by Gian Vincenzo Zuccotti, Chiara Mameli

Connect to this object online.

One year period of invasive pneumococcal disease in children from a tertiary care hospital in Turkey in the post-vaccine era by Gulnihan Ustundag, Eda Karadag-Oncel, Sebahat Sen-Tas, Ahu Kara-Aksay, Dilek Yilmaz-Ciftdogan, Nisel Yilmaz, Mehmet Ceyhan

Connect to this object online.

Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues by Johnna Perdrizet, Carlos Felipe S. Santana, Thais Senna, Rodrigo Fernandes Alexandre, Rodrigo Sini de Almeida, Julia Spinardi, Matt Wasserman

Connect to this object online.

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population by Derek Lytle, Ana Gabriela Grajales Beltrán, Johnna Perdrizet, Nassim Ait Yahia, Alejandro Cane, Benjamin Yarnoff, Ruth Chapman

Connect to this object online.

Incidence and severity of childhood pneumonia in the first year of life in a South African birth cohort: the Drakenstein Child Health Study by Dr. David M le Roux, MBChB, Landon Myer, PhD, Mark P Nicol, PhD, Heather J Zar, PhD

Connect to this object online.

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia by Youness Lagoubi, Mohamed Tahar Sfar, Jorge A. Gomez

Connect to this object online.

Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012-2018 by Larisa Savrasova, Angelika Krumina, Hedija Cupeca, Indra Zeltina, Anita Villerusha, Ilze Grope, Ludmila Viksna, Elina Dimina, Sooria Balasegaram

Connect to this object online.

Incidence of acute otitis media from 2003 to 2019 in children ≤ 17 years in England by Salini Mohanty, Bélène Podmore, Ana Cuñado Moral, Thomas Weiss, Ian Matthews, Eric Sarpong, Ignacio Méndez, Nawab Qizilbash

Connect to this object online.

Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012-2024 by Tzou-Yien Lin, Cheng-Hsun Chiu, Patrick CY Woo, Abdul Razak Muttalif, Raja Dhar, Leong Choon Kit, Graciela Morales, Egemen Ozbilgili

Connect to this object online.

The effectiveness of 13-valent pneumococcal vaccine against community acquired pneumonia in young children: a systematic review and meta-analysis by Ninel Revenco, Ana-Mihaela Balanuta, Dina Bujor, Adela Horodisteanu-Banuh, Olga Cirstea

Connect to this object online.

Hemophagocytic lymphohistiocytosis complicating invasive pneumococcal disease: a pediatric case report by Mitsuru Tsuge, Machiko Miyamoto, Reiji Miyawaki, Yoichi Kondo, Hirokazu Tsukahara

Connect to this object online.